Subscribe: MedWorm: Cardiogenic Shock
http://www.medworm.com/rss/medicalfeeds/conditions/Cardiogenic-Shock.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
abiomed  cardiogenic shock  cardiogenic  fda  heart  impella  medical  medpage today  new  patients  pci  shock  source  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Cardiogenic Shock

MedWorm: Cardiogenic Shock News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Cardiogenic Shock



Last Build Date: Thu, 15 Feb 2018 02:32:03 +0100

 



Abiomed wins expanded Impella FDA nod for elective, urgent high-risk PCI

Wed, 14 Feb 2018 15:54:49 +0100

Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5 and Impella CP heart pumps, now cleared for use during elective and urgent high risk percutaneous coronary intervention procedures. With the expansion, the Impella heart pump is cleared for use with patients with severe coronary artery disease, complex anatomy and a number of co-morbidities with or without depressed ejection fractions, the Danvers, Mass.-based company said. “This expanded FDA approval with moderately reduced ejection fraction validates our real-world experience using hemodynamic support in patients turned down for surgery with severe coronary artery disease. These patients who have often been managed medically in the past may have a new option for treatment,” Dr. Ehtisham...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock

Tue, 13 Feb 2018 15:18:06 +0100

DANVERS, Mass., Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an expanded U.S. Food and Drug Administ... Devices, Cardiology, FDA Abiomed, Impella, ventricular support, Cardiomyopathy, Cardiogenic Shock (Source: HSMN NewsFeed)



Abiomed touts expanded Impella heart pump indication, launches Women ’s Initiative

Tue, 13 Feb 2018 15:05:14 +0100

Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps, now cleared to provide treatment for heart failure associated with cardiomyopathy leading to cardiogenic shock, including peripartum and postpartum cardiomyopathy. The approval follows a previous FDA indication the Danvers, Mass.-based company won in April 2016 that cleared the device for treating acute myocardial infarction cardiogenic shock and post-cardiotomy cardiogenic shock. Abiomed touts its Impella heart pumps as the only percutaneous temporary ventricular support devices with FDA approval for cardiogenic shock in the setting of cardiomyopathy, according to a press release. The company also announced a new Women’s Initiative, which will ...



Living too far from advanced cardiac care decreases your odds of survival

Wed, 31 Jan 2018 05:00:00 +0100

(Elsevier) A new study published in the Canadian Journal of Cardiology determined that patients with acute cardiac syndrome (ACS) and cardiogenic shock (CS), who live far from the only cardiac catheterization facility in Nova Scotia, Canada, have a survival rate about half that of patients with more direct access. (Source: EurekAlert! - Medicine and Health)



Qool Therapeutics raises $8m to support temp management device

Tue, 28 Nov 2017 16:53:40 +0100

Early stage med device developer Qool Therapeutics said today it raised $8 million in a Series A-1 round to support development and trials of its Qool device designed for targeted temperature management and exercise recovery. Joining the funding round was Zhongji Holdings and Join Medical Technology, Tampcap LLC, BrilliMedical International, BioPacific Investors, Western Technology Investment and FundRx, the Silicon Valley-based company said. Qool Therapeutics said that in addition to the funding, it has also received an award from the US Department of Defense’s Defense Innovation unit Experimental organization. The company’s Qool device is designed for targeted temperature management and exercise recovery and is intended for use with multiple conditions. Those conditions inclu...



Revascularization in CS: Keep It Simple and Get Out of Dodge Revascularization in CS: Keep It Simple and Get Out of Dodge

Mon, 13 Nov 2017 18:35:06 +0100

Drs Harrington, Batchelor, and O'Donoghue discuss the implications of the TCT late-breaking CULPRIT SHOCK trial testing culprit-only vs multivessel revascularization in unstable patients in cardiogenic shock.theheart.org on Medscape (Source: Medscape Today Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Nov 3 Cardiology News Nov 3 Cardiology News

Fri, 03 Nov 2017 18:25:09 +0100

The ORBITA sham-control PCI study, Watchman, revascularization in cardiogenic shock, Absorb BVS, quality-of-life outcomes after PCI or bypass, and chronic total occlusion PCI are discussed in this week's podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)



Successful cardiogenic shock treatment using a percutaneous left ventricular assist device

Tue, 31 Oct 2017 04:00:00 +0100

(Osaka University) The Cardiovascular Surgery Group at Osaka University succeeded in minimally invasive treatment of a patient with acute heart failure due to medical treatment-resistant cardiogenic shock by making use of Impella, a percutaneous auxiliary artificial heart, for the first time in Japan. This method is anticipated as a new therapy for treating patients with acute heart failure due to medical treatment-resistant cardiogenic shock. (Source: EurekAlert! - Medicine and Health)



Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?

Tue, 31 Oct 2017 04:00:00 +0100

(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)



Multivessel PCI Not Best in Cardiogenic Shock

Mon, 30 Oct 2017 17:08:02 +0100

(MedPage Today) -- Trial data show mortality disadvantage versus treating culprit lesions only (Source: MedPage Today Nephrology)



New AHA Scientific Statement on Cardiogenic Shock New AHA Scientific Statement on Cardiogenic Shock

Thu, 26 Oct 2017 17:12:30 +0100

The statement provides a management algorithm integrating medical, surgical, and mechanical circulatory support therapies and calls for the development of regionalized systems of care.Medscape Medical News (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Abiomed nearly triples fiscal Q2 profits, crushes earnings expectations

Thu, 26 Oct 2017 11:26:40 +0100

Abiomed (NSDQ:ABMD) today said that its fiscal second-quarter profits nearly tripled and crushed the consensus earnings forecast on a nearly 30% sales increase. The Danvers, Mass.-based percutaneous heart pump maker posted profits of $24.5 million, or 54¢ per share, on sales of $132.8 million for the three months ended Sept. 30, for a bottom-line gain if 176.1% on sales growth of 29.0% compared with fiscal Q2 2017. Analysts on Wall Street were looking for EPS of 38¢ on sales of $131.1 million. “This quarter, we set new records for supporting patients in the U.S. and Germany and we continue to observe improved clinical outcomes with our education and training initiatives,” chairman, president & CEO Michael Minogue said in prepared remarks. “I am proud of the teamR...



TCT 2017: Rich in Clinical Trials, Star Power TCT 2017: Rich in Clinical Trials, Star Power

Tue, 17 Oct 2017 15:03:41 +0100

Oscar-winner Tom Hanks headlines a conference that will feature clinical trials looking at management of left main disease, cardiogenic shock, and bioabsorbable scaffolds.Medscape Medical News (Source: Medscape Medical News Headlines)



MAUDE: Post-TAVR Leaflet Thrombosis Not Benign MAUDE: Post-TAVR Leaflet Thrombosis Not Benign

Fri, 08 Sep 2017 21:01:43 +0100

While post-TAVR leaflet thrombosis can cause valve dysfunction or even cardiogenic shock and death, the question remains whether there's justification for routine anticoagulation given its inherent risks.Medscape Medical News (Source: Medscape Medical News Headlines)



Stenting Safe, More Popular for Oldest Old

Wed, 05 Jul 2017 17:00:00 +0100

(MedPage Today) -- Cardiogenic shock, no-reflow still problems in 90-year-olds (Source: MedPage Today Cardiovascular)



Abiomed touts survival benefits in Impella 2.5 cardiogenic shock PCI treatment study

Mon, 03 Jul 2017 19:11:49 +0100

Abiomed (NSDQ:ABMD) today released results from a study of its Impella 2.5 heart pump examining the use of the device in patients with acute myocardial infarction complicated by cardiogenic shock, touting survival benefits associated with the device. Results from the Danvers, Mass.-based company’s study were published in the Journal of Interventional Cardiology. Data from the 36-patient retrospective study came from real-world outcomes with the Impella 2.5 during percutaneous coronary interventions on unprotected left main coronary arteries, Abiomed said. The study aimed to analyze whether the initiation of hemodynamic support before PCI would improve survival compared to support post-PCI. Results indicated that patients treated with the Impella pre-PCI had survival rates of 55% at ...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




The Medical Emergency Of Otto Warmbier

Thu, 22 Jun 2017 23:01:38 +0100

All that the doctors who treated Cincinnati, Ohio resident Otto Warmbier knew is what they had seen or maybe read in the news. They knew he had just been released on June 13 from imprisonment in North Korea where he had been held by for more than 17 months. He had been sentenced in March 2016 to 15 years of hard labor for allegedly removing a propaganda poster from a wall at a Pyongyang hotel where he had been staying. The University of Virginia honors student had been visiting the authoritarian state during a five-day trip with a group called Young Pioneer Tours, which is a group out of China – an important note. Otto Warmbier’s ordeal began on Jan. 2, 2016 when he was removed from a flight that was about to leave Pyongyang, the capital of North Korea, by two North Korean offi...



Datascope joins Maquet countersuit against Abiomed

Fri, 16 Jun 2017 19:52:02 +0100

Getinge‘s (PINK:GETI B) Datascope said today it is filing a motion to join fellow Getinge company Maquet‘s patent infringement case against Abiomed (NSDQ:ABMD). The Wayne, N.J.-based company said it is asserting counterclaims which allege that Abiomed engaged in false advertising to promote that its Impella device was superior to Datascope’s intra-aortic baloon pumps. Datascope said that, simultaneously, Maquet will be expanding the infringement case by alleging that most Impella models infringe upon 3 Maquet patents, bringing the total number of patents in the suit to 6. In Datascope’s counterclaims, the company asserts that Abiomed “engaged in a pattern of intentional and widespread false advertising regarding Impella compared with IABP in violation of fed...






Abiomed launches 3rd-gen Impella CP heart pump

Tue, 09 May 2017 18:23:21 +0100

Abiomed (NSDQ:ABMD) said today it launched a 3rd generation Impella CP heart pump, touting new features and improved performance with the new model. The Danvers, Mass.-based company said that the 3rd-gen device includes new features that allow for better care during percutaneous coronary interventions in high risk patients and for patients being treated with the Impella in the ICU. “The ability to introduce the Impella device simply and swiftly even in the presence of challenging femoral or iliac arteries will be valuable for interventional cardiologists caring for high-risk patients during PCI and for those in cardiogenic shock. Enhanced flows will be very useful, as will the new guide wire repositioning unit which expands the options for access site closure or device exchanges,R...



Abiomed dips on missed Q4 earnings, despite sales beat

Thu, 04 May 2017 13:35:28 +0100

Share prices for Abiomed (NSDQ:ABMD) dipped today after the company reported fiscal 4th-quarter earnings that missed expectations, despite a top-line gain of nearly 33%. The Danvers, Mass.-based heart pump maker posted profits of $14.9 million, or 33¢ per share, on sales of $124.7 million for the 3 months ended March 31, for a bottom-line increase of 35.5% on sales growth of 32.7% compared with Q4 2016. But analysts on Wall Street were looking for earnings per share of 35¢; Abiomed topped the consensus Street estimate for sales by more than $2 million. Full-year profits were $52.1 million, or $1.17 per share, on sales of $445.2 million, representing profit growth of 36.6% on sales growth of 35.1% compared with fiscal 2016. “Abiomed remains 1 of the fastest-growing GAAP-profitable...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




6 Variables Can Predict Mortality Risk in Cardiogenic Shock

Thu, 13 Apr 2017 19:00:00 +0100

Variables from Intraaortic Balloon Pump in Cardiogenic Shock trial ID short - term mortality risk (Source: Pulmonary Medicine News - Doctors Lounge)



Abiomed doubles Danvers footprint

Thu, 30 Mar 2017 18:25:01 +0100

Abiomed (NSDQ:ABMD) today opened its expanded headquarters in Danvers, Mass., which more than doubles its footprint in the Bay State. Gov. Charlie Baker helped Abiomed CEO Mike Minogue and patient survivors to cut the ribbon on the $40 million, 160,000-square-foot HQ north of Boston. Abiomed makes the Impella line of percutaneous heart pumps, which are designed to provide cardiac support to heart failure patients during PCI procedures. The expansion adds new R&D and manufacturing facilities and a clinical training facility called the Heart Recovery Institute. “Today we recognize 35 years of dedication and hard work by all the people who made this possible — from employees, to customers, to patients, to investors,” Minogue said in prepared remarks. “We celebrate our...



Impella Pump Takes Positive Turn in Cardiogenic Shock Study Impella Pump Takes Positive Turn in Cardiogenic Shock Study

Mon, 27 Mar 2017 16:00:00 +0100

After the Impella heart pump showed no added benefit in cardiogenic shock over less costly balloon pumps in prior studies, applying best practices appears to be paying off with the device.Heartwire from Medscape (Source: Medscape Cardiology Headlines)



MassDevice.com +5 | The top 5 medtech stories for December 7, 2016

Wed, 07 Dec 2016 20:00:19 +0100

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Baxter releases infusion pump programming software Baxter launched its Sigma Spectrum Safety Management System this week at the American Society of Health-System Pharmacists meeting. The infusion pump system consists of an analytics software and a suite of remote professional services for cyber-security monitoring. The Deerfield, Ill.-based company said its Sigma Spectrum system was developed t...



FDA adds high-risk indication to Abiomed ’ s Impella CP heart pump

Wed, 07 Dec 2016 15:46:20 +0100

Abiomed (NSDQ:ABMD) said today that it won an expanded indication from the FDA for its Impella CP heart pump for high-risk patients. The Impella CP device, which won pre-market approval earlier this year for up to 4 hours of treating patients for cardiogenic shock after acute myocardial infarction or cardiac surgery, can now be used to for up to 6 hours during high-risk percutaneous coronary interventions, Danvers, Mass.-based Abiomed said. “This latest approval for Impella expands the hemodynamic options for the cardiovascular community to effectively revascularize severely ill patients who have limited options and high mortality risk,” Dr. Jeffrey Moses, of New York City’s Columbia University Medical Center, said in prepared remarks. “Backed by clinical data ...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Abiomed launches quality assurance program for Impella heart pump

Tue, 01 Nov 2016 22:46:52 +0100

Abiomed (NSDQ:ABMD) said today it launched the Impella quality assurance program, looking to improve outcomes for cardiogenic shock and protected PCI patients. The Danvers, Mass.-based company said the program will use data from its IQ Database, which includes observational quality assurance data on over 95% of Impella patients since 2008, including more than 44,000 Impella case entries. The IQ program will complement best practices alongside Abiomed’s 250-person clinical field team, the company said. “Abiomed has created the largest high-risk PCI and cardiogenic shock database of real-world evidence with different levels of analysis from observational quality assessment, to IRB prospective registries, to FDA prospective randomized studies. We believe that by sharing our data...



Japanese regulators approve Abiomed ’ s Impella heart pumps

Tue, 27 Sep 2016 17:16:12 +0100

Abiomed (NSDQ:ABMD) said today that it won approval from the Japanese Ministry of Health, Labor & Welfare’s Pharmaceuticals & Medical Devices Agency for its Impella line of heart pumps. The Danvers, Mass.-based company said its devices are the “1st and only percutaneous temporary ventricular support devices” to win Japanese PMDA approval and be deemed safe and effective for their indication. “This approval marks a significant milestone to provide Impella hemodynamic support for heart failure patients. We commend the dedication of Japanese physicians and regulatory bodies in searching for new treatment options to improve patient outcomes and quality of life, and enable cost-effective solutions. We are pleased that the field of heart recovery with percutane...



A Novel Approach to the Shocky Child

Tue, 27 Sep 2016 00:02:05 +0100

  Start with three quick bedside ultrasounds and you might avoid an unnecessary IV push An 11-year-old boy is brought to your emergency department following a few hours of persistent vomiting, irritability and decreasing activity. His mother also reports about two days of fever, decreased appetite and nasal stuffness. On initial evaluation, his vital signs include a heart rate of 128 beats/minute, blood pressure of 82/64 mmHg, respirations of 24 breaths/minute and temperature of 101.50F. Pulse oximetry reveals 98% saturation on room air while capillary refill time is approximately 5 seconds. His activity is reduced and skin mottling is evident. His rate and depth of breathing is, however, only slightly increased and his lungs are clear. It is apparent that your patient is in shock and...



Public Reporting for PCI, Cardiogenic Shock: Clarity or Confusion? Public Reporting for PCI, Cardiogenic Shock: Clarity or Confusion?

Thu, 11 Aug 2016 22:09:21 +0100

"It may simply be time to recognize that mortality following PCI is the wrong metric" to measure quality across diverse clinical scenarios, experts suggest.Heartwire from Medscape (Source: Medscape Cardiology Headlines)



Abiomed posts solid Q1, lifts full year outlook

Thu, 28 Jul 2016 16:50:07 +0100

Abiomed (NSDQ:ABMD) lifted its revenue guidance for the year after posting a Street-beating 1st quarter today. The Danvers, Mass.-based company reported profits of $12.9 million, or 29¢ per share, on sales of $103 million for the 3 months ended June 30. That amounts to a healthy 45.7% bottom-line gain as sales grew 40.3% compared with the same period last year. Abiomed handily beat Wall Street analyst’s expectations of 23¢ in EPS and $97.2 million in revenue. “Abiomed is creating a new era of medicine focused on the field of heart recovery and offering new treatment paradigms for high risk heart failure patients. With an estimated 6% U.S. Impella penetration rate, we are prepared for continued growth within the Protected PCI and emergent indications. Outside the U.S., we stand re...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




With End of Public Reporting, Better Tx of Cardiogenic Shock in NY (CME/CE)

Wed, 27 Jul 2016 20:35:01 +0100

(MedPage Today) -- Did reporting compromise care by increasing risk aversion? (Source: MedPage Today Public Health)



A case of mushroom poisoning with Russula subnigricans: development of rhabdomyolysis, acute kidney injury, cardiogenic shock, and death - Cho JT, Han JH.

Thu, 07 Jul 2016 07:23:23 +0100

Mushroom exposures are increasing worldwide. The incidence and fatality of mushroom poisoning are reported to be increasing. Several new syndromes in mushroom poisoning have been described. Rhabdomyolytic mushroom poisoning is one of new syndromes. Russula... (Source: SafetyLit)



Opinion Makers: Impella for Cardiogenic Shock

Wed, 06 Jul 2016 16:00:00 +0100

(MedPage Today) -- William O'Neill, MD, on why mortality of less than 20% is "very achievable" (Source: MedPage Today Cardiovascular)



Revascularization Strategy in Acute MI With Cardiogenic ShockRevascularization Strategy in Acute MI With Cardiogenic Shock

Thu, 14 Apr 2016 09:17:32 +0100

What is the optimal revascularization strategy in patients with multivessel disease and acute myocardial infarction complicated by cardiogenic shock? American Heart Journal (Source: Medscape Today Headlines)



Abiomed Impella® Therapy Receives FDA Approval For Cardiogenic Shock After Heart Attack Or Heart Surgery

Mon, 11 Apr 2016 04:58:23 +0100

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella 2.5™, Impella CP®, Impella 5.0™ and Impella LD™ heart pumps to provide treatment of ongoing cardiogenic shock. (Source: Medical Design Online News)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




MassDevice.com +5 | The top 5 medtech stories for April 8, 2016

Fri, 08 Apr 2016 19:00:08 +0100

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Monteris wins FDA IDE clearance for NeuroBlate trial Monteris Medical said today it won FDA investigational device exemption clearance for a trial of its NeuroBlate system for treating medically refractory epilepsy. The NeuroBlate system is designed to ablate, necrotize or coagulate soft tissue during neurosurgery procedures through laser thermotherapy, and is not intended for any specific dise...



FDA Approves Impella Heart Pumps for Cardiogenic ShockFDA Approves Impella Heart Pumps for Cardiogenic Shock

Fri, 08 Apr 2016 18:02:40 +0100

The entire family of Impella left side heart pumps has been approved for cardiogenic shock. FDA Approvals (Source: Medscape Medical News Headlines)



Abiomed Adds Cardiogenic Shock to Approved Indications

Fri, 08 Apr 2016 04:00:00 +0100

(Source: MDDI)



FDA clears Abiomed’s Impella with indication for cardiogenic shock

Thu, 07 Apr 2016 21:43:40 +0100

Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval indications for its Impella line of percutaneous heart pumps to treat patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. The Impella devices are now indicated for the stabilization of a patient’s hemodynamics, unloading of the left ventricle, perfusion of the end organs and to allow for recovery of the native heart, according to the Danvers, Mass.-based company. “Abiomed would like to recognize our customers, physicians, nurses, scientists, regulators and employees for their last fifteen years of circulatory support research and clinical applications. This FDA approval marks a significant milestone in the treatment of heart disease. The new medical field of heart mu...



FDA approves Abiomed’s Impella with indication for cardiogenic shock

Thu, 07 Apr 2016 21:43:40 +0100

Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval indications for its Impella line of percutaneous heart pumps to treat patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. The Impella devices are now indicated for the stabilization of a patient’s hemodynamics, unloading of the left ventricle, perfusion of the end organs and to allow for recovery of the native heart, according to the Danvers, Mass.-based company. “Abiomed would like to recognize our customers, physicians, nurses, scientists, regulators and employees for their last fifteen years of circulatory support research and clinical applications. This FDA approval marks a significant milestone in the treatment of heart disease. The new medical field of heart mu...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




MassDevice.com +5 | The top 5 medtech stories for March 22, 2016

Tue, 22 Mar 2016 20:00:51 +0100

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. DeviceTalks Podcast: Cohera Medical CEO Patrick Daly Before Patrick Daly was tapped as chairman of AdvaMed’s Accel unit, which represents emerging medical device companies, the CEO of Cohera Medical sat down with MassDevice.com Executive Editor Brad Perriello at DeviceTalks Raleigh. Daly, who founded the absorbable surgical adhesives and sealants company in 2006, has led 4 funding rounds tota...



Abiomed, FDA come to terms on Impella PMA requirements

Tue, 22 Mar 2016 12:57:09 +0100

Abiomed (NSDQ:ABMD) said yesterday that it came to terms with the FDA over the indications for use for its Impella line of cardiac assist devices and doesn’t believe it will have to appear before 1 of the agency’s advisory panels. Danvers, Mass.-based Abiomed said the federal safety watchdog agreed on the indication for treating patients in cardiogenic shock after a heart attack or cardiac surgery with its Impella 2.5, Impella CP, Impella 5.0 and Impella LD devices. “Based on the information available to the company to date, including multiple discussions with the FDA, the company no longer anticipates the requirement for an FDA advisory panel prior to the PMA approval,” the company said in a regulatory filing. Abiomed said it submitted data from its 415-patient R...



Scorpion envenomation-induced acute thrombotic inferior myocardial infarction - Baykan AO, Gür M, Acele A, Şeker T, Çaylı M.

Thu, 03 Mar 2016 20:19:31 +0100

The occurrence of a serious cardiac emergency following scorpion envenomation has rarely been reported and, when so, mostly presented as non-ST segment elevation myocardial infarction, cardiogenic shock, or myocarditis. Possible mechanisms include imbalanc... (Source: SafetyLit)



Early Risk Period Seen for Survivors of Cardiogenic Shock

Tue, 16 Feb 2016 20:00:00 +0100

(MedPage Today) -- In-hospital mortality declining but a vulnerable time follows for rehospitalization, studies say (Source: MedPage Today Cardiovascular)



Heart attack patients with cardiogenic shock fair well 60 days post-discharge

Mon, 15 Feb 2016 20:23:28 +0100

Heart attack patients who experience cardiogenic shock have a higher risk of death or rehospitalization than non-shock patients in the first 60 days post-discharge, but by the end of the first year, the gap between the two groups narrows, according to a study. (Source: ScienceDaily Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Severe bupropion overdose and ECMO: two great saves

Fri, 12 Feb 2016 05:29:54 +0100

ChaNaWiT/shutterstock.com 3.5 out of 5 stars Two Cases of Refractory Cardiogenic Shock Secondary to Bupropion Successfully Treated with Veno-Arterial Extracorporeal Membrance Oxygenation. Heise CW et al. J Med Toxicol 2016 Feb 8 [Epub Ahead of Print] Abstract This awesome, exciting paper from Banner University Medical Center in Phoenix describes two teenagers with severe bupropion overdose who survived refractory cardiac arrest after veno-arterial extracorporeal membrane oxygenation (VA-ECMO): Case 1: A 15-year-old girl was brought to hospital after ingesting up to 90 150-mg bupropion tablets. She had a seizure en route and arrived with pulseless electrical activity (PEA). Return of spontaneous circulation was achieved after 20 minutes of cardiopulmonary resuscitation. She was sent by a...



Registry Finds Mounting Deaths With Cardiogenic Shock (CME/CE)

Fri, 22 Jan 2016 17:30:00 +0100

(MedPage Today) -- Worrying trend despite years of clinician experience (Source: MedPage Today Cardiovascular)



Xenios expands manufacturing, R&D footprint

Tue, 01 Dec 2015 21:10:37 +0100

Xenios said today it expanded its research & development and manufacturing operations to include a new combined facility. The Reutlingen, Germany R&D and manufacturing facility was added as the company continues on what it calls an “aggressive growth strategy.” “Given that no other company except Xenios is offering minimally invasive lung and heart therapies on 1 platform, and given that the Xenios platform provides fundamental advantages for patients with its minimally invasive lung and heart therapies, Xenios is growing rapidly. As a direct result of the recent significant cash infusion from existing investors led by Zukunftsfonds Heilbronn (ZFHN), which we announced in September, Xenios is able to enlarge its commercial operations per plan,” mana...



Xenios wins CE Mark for I-Cor cardiac assist device

Wed, 25 Nov 2015 14:37:01 +0100

Xenios said yesterday that it won CE Mark approval in the European Union for its I-Cor synchronized cardiac assist device, touting it as the world’s 1st “heartbeat-synchronized” cardiac assist for cardiogenic shock and high-risk interventions. Heilbronn, Germany-based Xenios, which claimed in September to have drummed up an 8-figure funding round, said the I-Cor system is designed to provide “beat-to-beat” cardiac assistance using a miniature pump “with synchronized pulses that are superimposed over the patient’s weakened heartbeats.” “European regulatory approval of the I-Cor synchronized cardiac assist system now makes possible a whole new era for percutaneous cardiac assist,” managing director Dr. Georg Matheis said in pr...



TCT 2015 Roundup: St. Jude Medical’s new HeartMate PHP pump

Wed, 14 Oct 2015 18:43:03 +0100

St. Jude Medical (NYSE:STJ) said today that its newly acquired HeartMate PHP heart pump met its safety and efficacy endpoints in the Shield I trial used to back its CE Mark approval last summer. The results from Shield I’s 1st 30 patients led to the CE Mark nod in July. Today St. Jude said data from 46 subjects passed the primary safety endpoint of a composite of major adverse events and the primary efficacy endpoint of freedom from hemodynamic compromise during percutaneous coronary intervention. The study results, released today at the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco, also showed low complication rates, including no incidence of device-related cardiac death, myocardial infarction or intraprocedural hypotension. St. Jude acquired the...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




TCT 2015: Thrombectomy no benefit in Medtronic’s Export studies

Tue, 13 Oct 2015 19:00:37 +0100

Thrombus aspiration in heart attack patients showed no benefit and raised the risk of stroke, according to a pair of studies of percutaneous coronary interventions using Medtronic‘s (NYSE:MDT) Export aspiration catheter, presented today at the annual Transcatheter Cardiovascular Therapies conference in San Francisco. Early thrombectomy’s promise Totaled? The 10,064-patient Total study compared PCI alone and PCI with thrombectomy in ST-elevated myocardial infarctions within 12 hours of onset. The primary endpoint (a composite of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or class IV heart failure) at 1 year was 8% for both arms of the trial (395 of 5,035 thrombectomy patients, 394 of 5,029 PCI-only patients). Cardiovascular death occurred in 4...



Xenios claims ‘significant’ 8-figure funding round

Wed, 23 Sep 2015 22:12:56 +0100

Lung and heart therapy device developer XENiOS AG said today it received a “significant” round of funding, claiming the amount was in the 8-figure range. The Heilbronn, Germany-based company is developing a minimally invasive combined lung and heart therapy device on a single platform. “No other company except XENiOS is offering minimally invasive disposable lung and heart therapies on 1 platform. The XENiOS platform provides fundamental advantages with its minimally invasive lung and heart therapies. Patients are awake and mobile. Self-determined patients facilitate improved outcomes. There is no ventilator-associated lung injury and pneumonia. Additionally, the XENiOS platform maintains a physiologic natural pulse designed to protect the heart,” managing directo...



Case report: use of ECMO in colchicine poisoning

Fri, 11 Sep 2015 06:02:22 +0100

Colchicum autumnale (Autumn crocus) 3.5 out of 5 stars Extracorporeal life support in the treatment of colchicine poisoning. Boisramé-Helms J et al. Clin Toxicol 2015;53:827-829. Abstract Colchicine toxicity occurs roughly in 3 phases. During the initial 24 hours, severe gastrointestinal symptoms — nausea, vomiting, and diarrhea — can cause hypotension and shock if fluid losses are not adequately replaced. During the second phase, severe toxicity can manifest with pancytopenia, sepsis, rhabdomyolysis, and renal failure. In addition, within days after ingestion, patients can develop cardiogenic shock and sudden cardiac death. This fascinating case report — from the Nouvel Hôpital Civil in Strasbourg, France — describes the use of veno-arterial extracorporeal membrane oxygenation ...



Extracorporeal life support is 'bridge-to-life' for patients with sudden onset cardiogenic shock

Thu, 20 Aug 2015 17:01:24 +0100

The ideal management strategy for primary cardiogenic shock is a matter of debate. After some early discouraging experiences, the use of extracorporeal life support for patients with cardiogenic shock is having a resurgence. A report finds that patients who have an acute onset of cardiogenic shock, for example following a heart attack, and are placed on extracorporeal life support, fare better than those who have a chronic cardiac pathology. (Source: ScienceDaily Headlines)



Study: Manual thrombectomy increases stroke risk

Mon, 20 Jul 2015 19:12:29 +0100

Routine percutaneous coronary interventions with manual thrombectomies increase the risk of stroke compared to PCI alone, according to a new substudy published last month. The substudy, published online already and set to go to print in the European Heart Journal, examined a 10,058-patient cohort from the earlier Total study of PCI and manual thrombectomies to better understand the increase in stroke rate. The new analysis reported that the stroke difference was evident in as little as 48 hours, with 15 thrombectomy patients reporting an event versus 5 treated with only PCI. The overall risk was still low however, with a 0.3% risk associated with thrombectomy treatment and a 0.1% risk from PCI alone, according to the study. At 30-days, stroke rates in thrombectomy patients were more than d...



Catheter-Based VAD an Option for Cardiogenic Shock

Wed, 08 Apr 2015 14:35:00 +0100

(MedPage Today) -- Multi-society consensus statement also calls for national registries. (Source: MedPage Today Cardiovascular)



Glucagonoma-induced acute heart failure

Fri, 19 Dec 2014 12:00:00 +0100

Neuroendocrine tumours (NET) cover a broad spectrum of different hormone-secreting tumours of which, the glucagon-producing tumours of the pancreas are fairly rare and can be associated with syndromes such as MEN1. Zhang et al., report on a patient with glucagonoma who presented with left ventricular heart failure and developed cardiogenic shock despite therapy. Heart failure eventually regressed after initialising i.v. treatment with the somatostatin analogue octreotide. They therefore suggest that cardiac function should be monitored in a routine manner in all NET patients. Read full Case report by Zhang et al. (2014) Endocrinology, Diabetes, Metabolism Case Reports. Article ID: 14-0061; DOI:10.1530/EDM-014-0061 (Source: Society for Endocrinology)



Acute arsenic poisoning - Montelescaut E, Vermeersch V, Commandeur D, Huynh S, Danguy Des Deserts M, Sapin J, Ould-Ahmed M, Drouillard I.

Thu, 11 Dec 2014 20:30:15 +0100

We report the case of a patient admitted twelve hours after an ingestion of trioxide arsenic having survived thanks to a premature ... (Source: SafetyLit: All (Unduplicated))



Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels - Al-Abri SA, Meier KH, Colby JM, Smollin CG, Benowitz NL.

Thu, 30 Oct 2014 13:41:13 +0100

Context. 4-Fluoroamphetamine (4-FA) is a para-substituted phenethylamine-type synthetic stimulant that has in recent years gained popularity through internet blogs and market share according to confiscated drug data. No serious toxicity has previously been... (Source: SafetyLit: All (Unduplicated))

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Revised Article-Cardiogenic Shock

Mon, 27 Oct 2014 15:10:30 +0100

Cardiogenic shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away. (Source: National Heart, Lung, and Blood Institute Health Topics)



Review of scorpion envenomation

Tue, 12 Aug 2014 05:17:21 +0100

Asian forest scorpion 3 out of 5 stars Scorpion Envenomation. Isbister GK, Bawaskar HS. N Engl J Med 2014 Jul 31;371:457-463. Reference With over 1700 species of scorpions found all over the world, this brief review article is much too short and unfocused to provide more than a superficial overview of its topic. The authors point out that most scorpion stings cause, at most, minor toxicity with pain and other local effects only. Most serious envenomations are associated with the Buthidae family, which include the genus Centruroides, several of which are found in North America and commonly cause neuromuscular excitation. Major toxicity is associated with α-toxins, which inhibit deactivation of voltage-gated sodium channels causing sympathetic and parasympathetic autonomic excitation,...



Meta-analysis Questions Post-MI Use of Beta-blockersMeta-analysis Questions Post-MI Use of Beta-blockers

Mon, 07 Jul 2014 19:40:02 +0100

While beta-blockers reduce reinfarction and angina in the post-MI setting, there is no reduction in the risk of mortality. More important, the analysis showed an increased risk of heart failure and cardiogenic shock with beta-blockers when used post-MI. Heartwire (Source: Medscape Medical News Headlines)



Intra-Aortic Balloon Pump During Extracorporeal Life SupportIntra-Aortic Balloon Pump During Extracorporeal Life Support

Fri, 04 Jul 2014 12:02:38 +0100

Does the use of an intra-aortic balloon pump during extracorporeal life support improve survival in patients with myocardial infarction and cardiogenic shock? BMC Anesthesiology (Source: Medscape Today Headlines)



Transradial vs Transfemoral Coronary Intervention for AMITransradial vs Transfemoral Coronary Intervention for AMI

Mon, 16 Jun 2014 12:11:26 +0100

When cardiogenic shock occurs after AMI, which access point is safer for PCI? The Journal of Invasive Cardiology (Source: Medscape Today Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Do two dissimilar cases represent a case series?

Thu, 03 Apr 2014 01:27:48 +0100

2 out of 5 stars High-dose Insulin and Intravenous Lipid Emulsion Therapy for Cardiogenic Shock Induced by Intentional Calcium-Channel Blocker and Beta-Blocker Overdose: A Case Series. Doepker B et al. J Emerg Med 2014 Apr;46:486-490.   Abstract The problems with this confused and confusing paper start with the title, which suggests that it will describe a series patients who presented with overdose of a calcium-channel blocker (CCB) and beta-blocker (BB), who were treated with high-dose insulin (HDI) and intravenous lipid emulsion (ILE). Well, this may be a case series, but the series includes only 2 patients, and it would have been nice if this limitation was made clear in the title. In addition, only one patient took both a BB and CCBs: Patient 1: a 35-year-old man who took larg...



Mechanical Ventilation With PEEP in Cardiogenic ShockMechanical Ventilation With PEEP in Cardiogenic Shock

Mon, 16 Dec 2013 05:27:47 +0100

PEEP, is it safe to use in severe LV dysfunction and cardiogenic shock? Heart (Source: Medscape Today Headlines)



Influenza B-Induced Refractory Cardiogenic ShockInfluenza B-Induced Refractory Cardiogenic Shock

Wed, 04 Dec 2013 05:27:22 +0100

In this case report, a woman without known heart disease presented in profound cardiogenic shock. The cause? Influenza B. BMC Infectious Diseases (Source: Medscape Today Headlines)



Management of Cardiogenic Shock Complicating ACSManagement of Cardiogenic Shock Complicating ACS

Tue, 29 Oct 2013 13:05:16 +0100

Get up-to-date with current guidelines for best practices in the management of cardiogenic shock in the setting of acute coronary syndromes. Heart (Source: Medscape Today Headlines)



ESC: Balloon Pump Still No Help at 1 Year (CME/CE)

Wed, 04 Sep 2013 20:31:43 +0100

AMSTERDAM (MedPage Today) -- One year out, intra-aortic balloon pump (IABP) support still did not reduce mortality among patients with acute MI complicated by cardiogenic shock, extended follow-up of the IABP-SHOCK II trial showed. (Source: MedPage Today Cardiovascular)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




NJ thallium murder, laundry pods repackaged, Dr. Oz claims redemption: Weekly Web Review in Toxicology

Sun, 14 Jul 2013 19:14:42 +0100

  Was Dr. Oz right about arsenic and apple juice?: In 2011, Dr. Mehmet raised questions about levels of arsenic found in some commercial apple juices on his syndicated TV show.This week, ABC News reported that, for the first time, the U.S. Food and Drug Administration was considering establishing limits on the amount of inorganic arsenic allowed in apple juice. Apparently, Consumer Reports recently tested 88 juices and found that 10% had inorganic arsenic levels greater than that allowed in drinking water (10 parts per billion). Unfortunately, the ABC report does not make clear how much higher some levels were. This still seems to TPR to be many an public relations and political problem, and not a proven medical one. Although Dr. Oz says “we believe” that the small am...



Transradial PCI in Cardiogenic ShockTransradial PCI in Cardiogenic Shock

Tue, 02 Apr 2013 16:00:00 +0100

Why don't more patients in cardiogenic shock receive PCI -- via a transradial approach? American Heart Journal (Source: Medscape Today Headlines)



Improving Outcomes in Patients With Cardiogenic ShockImproving Outcomes in Patients With Cardiogenic Shock

Thu, 28 Mar 2013 16:00:00 +0100

Cardiogenic shock carries a grim prognosis. Can we turn it around? American Heart Journal (Source: Medscape Today Headlines)



Wrist PCI Viable in Unstable Shock (CME/CE)

Fri, 15 Mar 2013 15:00:00 +0100

(MedPage Today) -- The radial artery approach was safe in patients with cardiogenic shock undergoing percutaneous coronary intervention, and was associated with a reduced mortality compared with transfemoral access, a single-center study found. (Source: MedPage Today Cardiovascular)



Intraaortic balloon support for myocardial infarction with cardiogenic shock

Wed, 20 Feb 2013 18:05:22 +0100

Approximately 5-10% of patients after an acute myocardial infarction present with cardiogenic shock. Since 1968 intraaortic balloon counterpulsation is used to support the failing heart in cardiogenic shock. Read the full report by Prof. Holger Thiele along with comments from Professors Marco Tubaro (PROS) and Uwe Zeymer (CONS). Topics: Acute Coronary Syndromes (ACS) (Source: ESC News and Press)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




PCI by Radial Approach Feasible in Cardiogenic ShockPCI by Radial Approach Feasible in Cardiogenic Shock

Fri, 15 Feb 2013 17:00:00 +0100

Percutaneous coronary intervention (PCI) by the radial approach appears safe and feasible in patients with acute ST-elevation myocardial infarction (STEMI) and cardiogenic shock. Reuters Health Information (Source: Medscape Medical News Headlines)